InterCure Ltd. (INCR)
USD 1.56
(-1.89%)
USD 1.56
(-1.89%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 355.55 Million ILS | -8.52% |
| 2022 | 388.68 Million ILS | 76.93% |
| 2021 | 219.67 Million ILS | 237.78% |
| 2020 | 65.03 Million ILS | 628.6% |
| 2019 | 8.92 Million ILS | 0.0% |
| 2018 | - ILS | 0.0% |
| 2017 | - ILS | 0.0% |
| 2016 | - ILS | -100.0% |
| 2015 | 1.4 Million ILS | -75.2% |
| 2014 | 5.65 Million ILS | -31.51% |
| 2013 | 8.25 Million ILS | -2.59% |
| 2012 | 8.46 Million ILS | -29.82% |
| 2011 | 12.06 Million ILS | -8.76% |
| 2010 | 13.22 Million ILS | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 62.86 Million ILS | -14.43% |
| 2024 Q2 | 62.86 Million ILS | 0.0% |
| 2023 Q1 | 106.17 Million ILS | 0.54% |
| 2023 Q2 | 102.43 Million ILS | -3.52% |
| 2023 Q4 | 73.46 Million ILS | 0.0% |
| 2023 Q3 | 73.46 Million ILS | -28.28% |
| 2023 FY | 355.55 Million ILS | -8.52% |
| 2022 Q3 | 100.57 Million ILS | 5.56% |
| 2022 Q2 | 95.27 Million ILS | 9.23% |
| 2022 Q1 | 87.22 Million ILS | 9.45% |
| 2022 FY | 388.68 Million ILS | 76.93% |
| 2022 Q4 | 105.6 Million ILS | 5.01% |
| 2021 Q1 | 33.05 Million ILS | 21.99% |
| 2021 FY | 219.67 Million ILS | 237.78% |
| 2021 Q4 | 79.7 Million ILS | 29.19% |
| 2021 Q2 | 45.23 Million ILS | 36.85% |
| 2021 Q3 | 61.69 Million ILS | 36.4% |
| 2020 Q3 | 22.49 Million ILS | 101.14% |
| 2020 FY | 65.03 Million ILS | 628.6% |
| 2020 Q1 | 4.25 Million ILS | 132.99% |
| 2020 Q2 | 11.18 Million ILS | 162.62% |
| 2020 Q4 | 27.09 Million ILS | 20.43% |
| 2019 Q3 | 2.59 Million ILS | -6.45% |
| 2019 FY | 8.92 Million ILS | 0.0% |
| 2019 Q1 | 1.72 Million ILS | 0.0% |
| 2019 Q2 | 2.77 Million ILS | 61.17% |
| 2019 Q4 | 1.82 Million ILS | -29.64% |
| 2018 FY | - ILS | 0.0% |
| 2018 Q4 | - ILS | 0.0% |
| 2018 Q3 | - ILS | 0.0% |
| 2018 Q2 | - ILS | 0.0% |
| 2018 Q1 | - ILS | 0.0% |
| 2017 Q4 | - ILS | 0.0% |
| 2017 Q3 | - ILS | 0.0% |
| 2017 Q1 | - ILS | 0.0% |
| 2017 Q2 | - ILS | 0.0% |
| 2017 FY | - ILS | 0.0% |
| 2016 Q2 | - ILS | 0.0% |
| 2016 Q1 | - ILS | -100.0% |
| 2016 FY | - ILS | -100.0% |
| 2016 Q4 | - ILS | 0.0% |
| 2016 Q3 | - ILS | 0.0% |
| 2015 FY | 1.4 Million ILS | -75.2% |
| 2015 Q3 | 333.97 Thousand ILS | -26.98% |
| 2015 Q2 | 457.34 Thousand ILS | -16.24% |
| 2015 Q1 | 546.03 Thousand ILS | -46.9% |
| 2015 Q4 | 49.79 Thousand ILS | -85.09% |
| 2014 Q3 | 1.05 Million ILS | -18.91% |
| 2014 Q2 | 1.3 Million ILS | -36.54% |
| 2014 Q1 | 2.05 Million ILS | -11.94% |
| 2014 FY | 5.65 Million ILS | -31.51% |
| 2014 Q4 | 1.02 Million ILS | -2.77% |
| 2013 Q4 | 2.33 Million ILS | 38.32% |
| 2013 FY | 8.25 Million ILS | -2.59% |
| 2013 Q3 | 1.68 Million ILS | -9.64% |
| 2013 Q2 | 1.86 Million ILS | -24.04% |
| 2013 Q1 | 2.45 Million ILS | 30.56% |
| 2012 Q1 | 2.39 Million ILS | -20.59% |
| 2012 Q2 | 2.18 Million ILS | -8.71% |
| 2012 Q3 | 1.84 Million ILS | -15.73% |
| 2012 Q4 | 1.88 Million ILS | 2.16% |
| 2012 FY | 8.46 Million ILS | -29.82% |
| 2011 FY | 12.06 Million ILS | -8.76% |
| 2011 Q3 | 3.01 Million ILS | 0.0% |
| 2011 Q1 | 3.01 Million ILS | -8.76% |
| 2011 Q2 | 3.01 Million ILS | 0.0% |
| 2011 Q4 | 3.01 Million ILS | 0.0% |
| 2010 Q4 | 3.3 Million ILS | 0.0% |
| 2010 Q1 | 3.3 Million ILS | 0.0% |
| 2010 Q3 | 3.3 Million ILS | 0.0% |
| 2010 FY | 13.22 Million ILS | 0.0% |
| 2010 Q2 | 3.3 Million ILS | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Clever Leaves Holdings Inc. | 17.41 Million USD | -1941.414% |
| Alvotech | 91.43 Million USD | -288.863% |
| Alimera Sciences, Inc. | 80.75 Million USD | -340.292% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 26.964% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -602.91% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -1171.512% |
| Aytu BioPharma, Inc. | 81 Million USD | -338.943% |
| Bright Green Corporation | 401.49 Thousand USD | -88458.149% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 37.266% |
| Cosmos Health Inc. | 53.37 Million USD | -566.118% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -798.939% |
| Cronos Group Inc. | 88.84 Million USD | -300.213% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 65.062% |
| Journey Medical Corporation | 79.18 Million USD | -349.038% |
| Dynavax Technologies Corporation | 232.28 Million USD | -53.068% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -27208.218% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -2802.817% |
| Biofrontera Inc. | 34.07 Million USD | -943.565% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -177.211% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 47.324% |
| OptiNose, Inc. | 70.98 Million USD | -400.871% |
| Procaps Group, S.A. | 409.92 Million USD | 13.263% |
| ProPhase Labs, Inc. | 44.38 Million USD | -701.084% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -5358.983% |
| Radius Health, Inc. | 2.88 Billion USD | 87.664% |
| Rockwell Medical, Inc. | 83.61 Million USD | -325.242% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -1375.765% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -1375.765% |
| SCYNEXIS, Inc. | 140.14 Million USD | -153.711% |
| Safety Shot Inc | 202.67 Thousand USD | -175334.45% |
| SIGA Technologies, Inc. | 139.91 Million USD | -154.117% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -2691.936% |
| Silver Spike Investment Corp. | 11.72 Million USD | -2933.177% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Shineco, Inc. | 9.8 Million USD | -3527.405% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -18336.793% |
| Theratechnologies Inc. | 81.76 Million USD | -334.853% |
| Talphera, Inc. | 651 Thousand USD | -54516.436% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -1000.486% |
| Harrow Health, Inc. | 130.19 Million USD | -173.097% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 19.692% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 41.475% |
| Tilray Brands, Inc. | 788.94 Million USD | 54.933% |
| DURECT Corporation | 8.54 Million USD | -4059.488% |
| Incannex Healthcare Limited | 12 Thousand USD | -2962841.667% |
| Alpha Teknova, Inc. | 36.68 Million USD | -869.232% |
| Procaps Group S.A. | 409.92 Million USD | 13.263% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -6006.652% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 23.433% |
| Viatris Inc. | 15.42 Billion USD | 97.695% |
| PetIQ, Inc. | 1.1 Billion USD | 67.735% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 81.159% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 17.913% |
| Assertio Holdings, Inc. | 152.06 Million USD | -133.81% |
| Embecta Corp. | 1.12 Billion USD | 68.277% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| PainReform Ltd. | - USD | -Infinity% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -32931.526% |
| Alvotech | 91.43 Million USD | -288.863% |
| Hempacco Co., Inc. | 4.04 Million USD | -8688.554% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | -12.3% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 72.574% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -205.631% |
| Kamada Ltd. | 144.75 Million USD | -145.618% |
| Indivior PLC | 1.09 Billion USD | 67.47% |
| Evoke Pharma, Inc. | 5.18 Million USD | -6763.123% |
| Flora Growth Corp. | 76.07 Million USD | -367.396% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -32931.526% |
| Evolus, Inc. | 202.08 Million USD | -75.942% |
| HUTCHMED (China) Limited | 837.99 Million USD | 57.571% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 44.824% |
| Akanda Corp. | 2.16 Million USD | -16360.391% |